Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088718 · ClinicalTrials.gov registry record
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 44,671
- Enrollment target
NCT07088718: Completed study, sponsored by Brigham and Women's Hospital.
NCT07088718 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 44,671 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07088718 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 44,671 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
To evaluate the comparative effect of tirzepatide vs dulaglutide on time to first occurrence of MACE (all-cause mortailty, myocardial infarction, or death) in patients with T2DM and an established CVD when following the eligibility criteria of the SURPASS-CVOT trial: Individuals aged 40 years or older with T2DM and an established CVD.
Interventions
- DRUG Tirzepatide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44,671 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-07-30 |
What the finished NCT07088718 record still lists
NCT07088718 is an observational study that tracks outcomes without assigning an intervention. Its 44,671 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07088718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07088718 about?
NCT07088718 is a clinical study titled "Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07088718?
This trial is currently completed. The enrollment target is 44,671 participants. The study started on 2024-10-01. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT07088718?
The interventions under investigation include: Tirzepatide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07088718?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT03977402 · 47,500 participants
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI